-
Je něco špatně v tomto záznamu ?
A computational study suggests that replacing PEG with PMOZ may increase exposure of hydrophobic targeting moiety
A. Magarkar, T. Róg, A. Bunker,
Jazyk angličtina Země Nizozemsko
Typ dokumentu časopisecké články
- MeSH
- cholesterol chemie MeSH
- fosfatidylcholiny chemie MeSH
- hydrofobní a hydrofilní interakce MeSH
- lékové transportní systémy MeSH
- lidé MeSH
- ligandy MeSH
- liposomy chemie MeSH
- oligopeptidy chemie MeSH
- polyaminy chemie MeSH
- polyethylenglykoly chemie MeSH
- povrchové vlastnosti MeSH
- simulace molekulární dynamiky MeSH
- Check Tag
- lidé MeSH
- Publikační typ
- časopisecké články MeSH
In a previous study we showed that the cause of failure of a new, proposed, targeting ligand, the AETP moiety, when attached to a PEGylated liposome, was occlusion by the poly(ethylene glycol) (PEG) layer due to its hydrophobic nature, given that PEG is not entirely hydrophilic. At the time we proposed that possible replacement with a more hydrophilic protective polymer could alleviate this problem. In this study we have used computational molecular dynamics modelling, using a model with all atom resolution, to suggest that a specific alternative protective polymer, poly(2-methyloxazoline) (PMOZ), would perform exactly this function. Our results show that when PEG is replaced by PMOZ the relative exposure to the solvent of AETP is increased to a level even greater than that we found in previous simulations for the RGD peptide, a targeting moiety that has previously been used successfully in PEGylated liposome based therapies. While the AETP moiety itself is no longer under consideration, the results of this computational study have broader significance: the use of PMOZ as an alternative polymer coating to PEG could be efficacious in the context of more hydrophobic targeting ligands. In addition to PMOZ we studied another polyoxazoline, poly(2-ethyloxazoline) (PEOZ), that has also been mooted as a possible alternate protective polymer. It was also found that the RDG peptide occlusion was significantly greater for the case of both oxazolines as opposed to PEG and that, unlike PEG, neither oxazoline entered the membrane. As far as we are aware this is the first time that polyoxazolines have been studied using molecular dynamics simulation with all atom resolution.
Department of Physics University of Helsinki Helsinki Finland
Drug Research Program Faculty of Pharmacy University of Helsinki Helsinki Finland
Citace poskytuje Crossref.org
- 000
- 00000naa a2200000 a 4500
- 001
- bmc18016729
- 003
- CZ-PrNML
- 005
- 20180523095618.0
- 007
- ta
- 008
- 180515s2017 ne f 000 0|eng||
- 009
- AR
- 024 7_
- $a 10.1016/j.ejps.2017.03.008 $2 doi
- 035 __
- $a (PubMed)28285174
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a ne
- 100 1_
- $a Magarkar, Aniket $u Drug Research Program, Faculty of Pharmacy, University of Helsinki, Helsinki, Finland; Institute of Organic Chemistry and Biochemistry, Academy of the Sciences of the Czech Republic Prague, Czech Republic.
- 245 12
- $a A computational study suggests that replacing PEG with PMOZ may increase exposure of hydrophobic targeting moiety / $c A. Magarkar, T. Róg, A. Bunker,
- 520 9_
- $a In a previous study we showed that the cause of failure of a new, proposed, targeting ligand, the AETP moiety, when attached to a PEGylated liposome, was occlusion by the poly(ethylene glycol) (PEG) layer due to its hydrophobic nature, given that PEG is not entirely hydrophilic. At the time we proposed that possible replacement with a more hydrophilic protective polymer could alleviate this problem. In this study we have used computational molecular dynamics modelling, using a model with all atom resolution, to suggest that a specific alternative protective polymer, poly(2-methyloxazoline) (PMOZ), would perform exactly this function. Our results show that when PEG is replaced by PMOZ the relative exposure to the solvent of AETP is increased to a level even greater than that we found in previous simulations for the RGD peptide, a targeting moiety that has previously been used successfully in PEGylated liposome based therapies. While the AETP moiety itself is no longer under consideration, the results of this computational study have broader significance: the use of PMOZ as an alternative polymer coating to PEG could be efficacious in the context of more hydrophobic targeting ligands. In addition to PMOZ we studied another polyoxazoline, poly(2-ethyloxazoline) (PEOZ), that has also been mooted as a possible alternate protective polymer. It was also found that the RDG peptide occlusion was significantly greater for the case of both oxazolines as opposed to PEG and that, unlike PEG, neither oxazoline entered the membrane. As far as we are aware this is the first time that polyoxazolines have been studied using molecular dynamics simulation with all atom resolution.
- 650 _2
- $a cholesterol $x chemie $7 D002784
- 650 _2
- $a lékové transportní systémy $7 D016503
- 650 _2
- $a lidé $7 D006801
- 650 _2
- $a hydrofobní a hydrofilní interakce $7 D057927
- 650 _2
- $a ligandy $7 D008024
- 650 _2
- $a liposomy $x chemie $7 D008081
- 650 _2
- $a simulace molekulární dynamiky $7 D056004
- 650 _2
- $a oligopeptidy $x chemie $7 D009842
- 650 _2
- $a fosfatidylcholiny $x chemie $7 D010713
- 650 _2
- $a polyaminy $x chemie $7 D011073
- 650 _2
- $a polyethylenglykoly $x chemie $7 D011092
- 650 _2
- $a povrchové vlastnosti $7 D013499
- 655 _2
- $a časopisecké články $7 D016428
- 700 1_
- $a Róg, Tomasz $u Department of Physics, University of Helsinki, Helsinki, Finland.
- 700 1_
- $a Bunker, Alex $u Drug Research Program, Faculty of Pharmacy, University of Helsinki, Helsinki, Finland. Electronic address: alex.bunker@helsinki.fi.
- 773 0_
- $w MED00001639 $t European journal of pharmaceutical sciences official journal of the European Federation for Pharmaceutical Sciences $x 1879-0720 $g Roč. 103, č. - (2017), s. 128-135
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/28285174 $y Pubmed
- 910 __
- $a ABA008 $b sig $c sign $y a $z 0
- 990 __
- $a 20180515 $b ABA008
- 991 __
- $a 20180523095803 $b ABA008
- 999 __
- $a ok $b bmc $g 1300353 $s 1013569
- BAS __
- $a 3
- BAS __
- $a PreBMC
- BMC __
- $a 2017 $b 103 $c - $d 128-135 $e 20170309 $i 1879-0720 $m European journal of pharmaceutical sciences $n Eur. j. pharm. sci. (Print) $x MED00001639
- LZP __
- $a Pubmed-20180515